Identifying which patients will benefit most from immune checkpoint blockade (ICB) is an important clinical challenge. A study now finds that Vδ1+ γδ T cells are associated with better response to ICB in melanoma tumors with a lower neoantigen load and shows that some effector functions of PD-1+ Vδ1+ T cells are repressed after engagement of PD-1 by PD-L1.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Davies, D. et al. Nat. Cancer https://doi.org/10.1038/s43018-023-00690-0 (2024).
Schumacher, T. N. & Schreiber, R. D. Science 348, 69–74 (2015).
Gentles, A. J. et al. Nat. Med. 21, 938–945 (2015).
Moore, O. S. Jr. & Foote, F. W. Jr. Cancer 2, 635–642 (1949).
Sireci, G. et al. Hum. Immunol. 58, 70–82 (1997).
Cerapio, J. P. et al. OncoImmunology 10, 1939518 (2021).
Wu, Y. et al. Sci. Transl. Med. 11, eaax9364 (2019).
Harmon, C. et al. Nat. Can. 4, 1122–1137 (2023).
de Vries, N. L. et al. Nature 613, 743–750 (2023).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Widlund, H.R., Lynch, L. γδ T cells as unconventional targets of checkpoint blockade. Nat Cancer 5, 373–374 (2024). https://doi.org/10.1038/s43018-024-00735-y
Published:
Issue Date:
DOI: https://doi.org/10.1038/s43018-024-00735-y
